Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1–2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Respiratory Medicine Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007125000127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864399833595904 |
|---|---|
| author | Jun Sakakibara-Konishi Hirofumi Takahashi Kenichiro Ito Tomoo Ikari Yasuyuki Ikezawa Hidenori Kitai Megumi Furuta Yuta Takashima Tetsuaki Shoji Masahide Fukudo Satoshi Konno |
| author_facet | Jun Sakakibara-Konishi Hirofumi Takahashi Kenichiro Ito Tomoo Ikari Yasuyuki Ikezawa Hidenori Kitai Megumi Furuta Yuta Takashima Tetsuaki Shoji Masahide Fukudo Satoshi Konno |
| author_sort | Jun Sakakibara-Konishi |
| collection | DOAJ |
| description | Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1–2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. However, hypertension, aspartate aminotransferase increase, and alanine aminotransferase increase are the most common adverse events, and dose modification or discontinuation is required occasionally. Here, we describe a case who has response to 40 mg of selpercatinib every other day because the dose had to be adjusted owing to adverse events such as liver dysfunction. Dose modification of selpercatinib, according to adverse event incidences, may be considered, as selpercatinib may be effective in some cases even at very low concentrations. |
| format | Article |
| id | doaj-art-5af3ea18c9b24f948f0d8a778700eb6c |
| institution | Kabale University |
| issn | 2213-0071 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Respiratory Medicine Case Reports |
| spelling | doaj-art-5af3ea18c9b24f948f0d8a778700eb6c2025-02-09T05:00:24ZengElsevierRespiratory Medicine Case Reports2213-00712025-01-0153102176Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancerJun Sakakibara-Konishi0Hirofumi Takahashi1Kenichiro Ito2Tomoo Ikari3Yasuyuki Ikezawa4Hidenori Kitai5Megumi Furuta6Yuta Takashima7Tetsuaki Shoji8Masahide Fukudo9Satoshi Konno10Medical Network and Welfare Center, Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; Corresponding author. Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, N 15, W 7, Kita-ku, Sapporo, 0608638, Japan.Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanKKR Sapporo Medical Center, Sapporo, Hokkaido, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Miyagi, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanDepartment of Hospital Pharmacy, Sapporo Medical University Hospital, Sapporo, Hokkaido, JapanDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, JapanChromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1–2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. However, hypertension, aspartate aminotransferase increase, and alanine aminotransferase increase are the most common adverse events, and dose modification or discontinuation is required occasionally. Here, we describe a case who has response to 40 mg of selpercatinib every other day because the dose had to be adjusted owing to adverse events such as liver dysfunction. Dose modification of selpercatinib, according to adverse event incidences, may be considered, as selpercatinib may be effective in some cases even at very low concentrations.http://www.sciencedirect.com/science/article/pii/S2213007125000127Non-small cell lung cancerRET-rearranged lung cancerSelpercatinib |
| spellingShingle | Jun Sakakibara-Konishi Hirofumi Takahashi Kenichiro Ito Tomoo Ikari Yasuyuki Ikezawa Hidenori Kitai Megumi Furuta Yuta Takashima Tetsuaki Shoji Masahide Fukudo Satoshi Konno Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer Respiratory Medicine Case Reports Non-small cell lung cancer RET-rearranged lung cancer Selpercatinib |
| title | Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer |
| title_full | Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer |
| title_fullStr | Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer |
| title_full_unstemmed | Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer |
| title_short | Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer |
| title_sort | remarkable response to low dose of selpercatinib in a patient with ret rearranged non small cell lung cancer |
| topic | Non-small cell lung cancer RET-rearranged lung cancer Selpercatinib |
| url | http://www.sciencedirect.com/science/article/pii/S2213007125000127 |
| work_keys_str_mv | AT junsakakibarakonishi remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT hirofumitakahashi remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT kenichiroito remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT tomooikari remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT yasuyukiikezawa remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT hidenorikitai remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT megumifuruta remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT yutatakashima remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT tetsuakishoji remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT masahidefukudo remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer AT satoshikonno remarkableresponsetolowdoseofselpercatinibinapatientwithretrearrangednonsmallcelllungcancer |